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Abstract
Amyloid-b precursor protein (APP) plays a central role in pathogenesis of Alzheimer’s disease. APP has a short half-life and
undergoes complex proteolytic processing that is highly responsive to various stimuli such as changes in cellular lipid or
energy homeostasis. Cellular trafficking of APP is controlled by its large protein interactome, including dozens of cytosolic
adaptor proteins, and also by interactions with lipids. Currently, cellular regulation of APP is mostly studied based on
appearance of APP-derived proteolytic fragments to conditioned media and cellular extracts. Here, we have developed a
novel live-cell assay system based on several indirect measures that reflect altered APP trafficking and processing in cells.
Protein-fragment complementation assay technology for detection of APP-BACE1 protein-protein interaction forms the core
of the new assay. In a multiplex form, the assay can measure four endpoints: total cellular APP level, total secreted sAPP
level in media, APP-BACE1 interaction in cells and in exosomes released by the cells. Functional validation of the assay with
pharmacological and genetic tools revealed distinct patterns of cellular fates of APP, with immediate mechanistic
implications. This new technology will facilitate functional genomics studies of late-onset Alzheimer’s disease, drug
discovery efforts targeting APP and characterization of the physiological functions of APP and its proteolytic fragments.
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Introduction
Amyloid-b precursor protein (APP) is multifunctional glycopro-
tein and a source of several proteolytically generated bioactive
peptides [1,2]. Amyloid-b peptide (Ab) is a major constituent of
amyloid plaques, a pathological hallmark of Alzheimer’s disease
[3]. In the nervous system, soluble Ab has prominent inhibitory
effects on synaptic function and plasticity [4,5]. Ab is derived from
amyloid-b precursor protein (APP) via sequential proteolytical
cleavages by b-secretase (BACE1) and c-secretase [6,7]. Other
fragments, such as sAPP-a, sAPP-b and APP intracellular domain
(AICD), have paracrine and cell-autonomous regulatory functions,
which remain incompletely characterized [8–11]. In addition to
peptides from the well-characterized a-, b- and c/e cleavages, also
other cleavage products of APP have been described in specific
conditions [12–15].
APP has a rapid turnover in most cells types [16,17], and
protelolytic processing plays a central role in APP’s lifecycle and
functions [2,18]. While nonamyloidogenic processing of APP by a-
secretases takes mostly place at the cell surface, amyloidogenic b-
and c-secretase-mediated processing of APP occurs within
intracellular vesicular compartments, especially endosomes [19–
21]. Therefore, endocytosis and subcellular vesicular trafficking of
APP are major determinants of the cellular fate of APP [22]. The
APP trafficking and processing system is highly responsive to
various aspects of cellular metabolism and stress, including
alterations in lipid, Ca2+ and energy homeostasis [17,23–27]. A
complex interplay of proteins interacting with APP determines its
cellular trafficking and fate. Particularly, there seems to be a large
number of cytosolic adaptor proteins that interact with the
cytosolic domain of APP and regulate its internalization and
further subcellular trafficking [28]. Moreover, interaction with
membrane lipids also modulates APP trafficking and processing
[29,30].
A variety of methods have been applied for studying the cell
biology of APP. Western blot and ELISA are the standard
methods to study proteolytic fragments of APP. In addition,
techniques like affinity capture-mass spectrometry offer an
unbiased way for characterization of components of the APP
interactome [28,31,32], while fluorescence resonance energy
transfer (FRET)-based techniques have proven useful for visual-
ization and studying dynamics of individual protein-protein
interactions based on physical proximity in living cells [33,34].
Studying the complex cellular regulation of APP, especially the
dynamic features, would benefit from development of novel tools
that can be used in live cells, preferably with high-throughput
capacity.
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Among the more than 200 currently known protein interactors
of APP [28], BACE1 has attracted perhaps the most attention
[35]. Since BACE1-mediated amyloidogenic cleavage of APP is
the rate-limiting step in generation of Ab peptide, better
understanding of the dynamics of APP-BACE1 interaction could
help explain cellular mechanisms involved in the early stages of
pathogenesis of Alzheimer’s disease. Moreover, the normal
physiological function(s) of APP and its proteolytic fragments
remain poorly understood. Better understanding of the molecular-
level regulation of APP-BACE1 interaction can provide novel
insight into the cellular functions of these proteins. Here, we have
developed a novel approach for studying APP-BACE1 interaction
using a protein-fragment complementation assay (PCA) based on
the small Gaussia princeps luciferase (GLuc) [36]. This sensitive
APP-BACE1 protein-protein interaction assay was combined with
alkaline phosphatase-based detection of secreted sAPP fragments
providing a four-readout multiplexed assay platform capable of
delivering mechanistic details on how APP is regulated in live cells.
Materials and Methods
DNA plasmid construction
The original humanized Gaussia princeps PCA plasmids [36] were
donated by Dr. Stephan Michnick (Universite´ de Montre´al,
Canada) and were constructed in the pcDNA3.1/zeo (Invitrogen)
backbone. The hGLuc-tagged APP695 constructs were generated
and donated by Dr. Oksana Berezovska (Massachusetts General
Hospital, Boston, MA). All APP constructs used in this study
expressed the neuronal APP695 isoform lacking the KPI domain.
The cDNA of BACE1 was a gift from Dr. Dora Kovacs
(Massachusetts General Hospital, Boston, MA). For APP and
BACE1 (both type 1 transmembrane proteins), the hGLuc
fragment was placed in the cytosolic C-terminus after a
(GGGGS)2SG linker. The APP-hGLuc constructs were further
modified by fusing the secreted alkaline phosphatase (AP) fragment
to the N-terminus replacing the endogenous APP signal peptide
[pEAK12-AP/APP plasmid was a kind gift from Dr. Stephan
Lichtenthaler (Ludwig-Maximilians-Universita¨t Mu¨nchen, Ger-
many)] [37]. The identity of all constructs was confirmed by DNA
sequencing.
Cell culture, transfection and RNAi
Mouse Neuro-2A (N2A) neuroblastoma cells (ATCC) were
cultured in DMEM supplemented with 10% (v/v) FBS (Invitro-
gen), 1% (v/v) L-glutamine-penicillin-streptomycin solution
(Lonza) at 37uC in a water-saturated air, 5% CO2 atmosphere.
N2A cells were transfected with JetPEI (Polyplus) according to the
manufacturer’s instructions. The transfection conditions were
optimized so that on average at least 80% transfection efficiency
was reached. Gene silencing was achieved by co-transfection of
plasmids encoding shRNA for mouse GGA3 or mouse VPS35
(OpenBiosystems/Thermo Scientific). Gene silencing efficiency
was tested in N2A cells using Western blotting.
Protein fragment-complementation assay
N2A cells were plated on poly-L-lysine-coated white-wall 96-
well plates (PerkinElmer Life Sciences). 125 ng of plasmid DNA
was used for transient transfection per well, divided as follows:
58.75 ng of GLuc1 reporter plasmid, 58.75 ng of GLuc2 reporter
plasmid, and 7.5 ng of pRC/CMV-b-galactosidase (bGal) as an
internal vector control. In case of co-transfection with shRNA
plasmids, the ratios were as follows: GLuc1 27 ng, GLuc2 27 ng,
shRNA 40 ng and bGal 6 ng. Experiments were carried out 48 h
after transfection with four replicate wells used per experimental
condition. Briefly, the cells were washed with warm PBS and
placed in phenol red-free DMEM (Invitrogen) without serum. Test
compounds were added to the medium, and the cells were
incubated for 2–24 h. Brefeldin A (BFA) and Bafilomycin A1 were
purchased from Sigma. BACE inhibitor IV was obtained from
Calbiochem and DAPT was from Biomol (Enzo Life Sciences).
Dynole 34-2 was purhcased from Tocris/R&D Systems. DMSO
was used as a vehicle control. For detection of the hGLuc PCA
signal, the cells were exposed to well-by-well injections of 25 ml
(final concentration, 20 mM) of native coelenterazine (Nanolight
Technology), and the emitted luminescence was detected imme-
diately by flash luminometry using a Victor3 plate reader
(PerkinElmer Life Sciences). Individual experiments were repeated
three or four times. After measuring the PCA signal, cells were
lysed for bGal assay with 40 ml of lysis buffer/well (120 mM Tris-
HCl, pH 7.5, 120 mM NaCl, 6 mM MgSO4, 6% Triton X-100)
and incubated for 30 min at room temperature with mild shaking.
Then, 45 ml of bGal substrate o-nitrophenyl-b-D-galactopyrano-
side (Sigma, 4 mg/ml stock in sterile water) solution was combined
with 55 ml of cleavage buffer (120 mM sodium phosphate, pH 7.0,
24 mM KCl, 2.4 mM MgSO4, and 2.4 mM DTT), and 100 ml of
this solution was added per well. The plates were incubated at +
37uC for a further 30 minutes and absorbance was read at
405 nm.
Secreted alkaline phosphatase (SEAP) assay
Conditioned media was collected at indicated time points and
clarified by centrifugation at 5,0006g for 10 min. Secreted sAPP
was measured by a chemiluminescent Secreted Alkaline Phospho-
tase reporter gene assay (SEAP Assay; Roche Applied Science)
according to the manufacturer’s instructions.
Multiplex PCA
PCA part was adjusted by changing the ratios of plasmids for
transient transfection. 125 ng of plasmid DNA was divided as
follows: 33.75 ng of GLuc1 reporter plasmid, 83.75 ng of GLuc2
reporter plasmid, and 7.5 ng of bGal plasmid. 42 h after
transfection, the cells were washed with warm PBS and placed
in 130 ml of phenol red-free DMEM (Invitrogen) without serum.
Test compounds were added to the medium, and the cells were
incubated for 6 h. Media was collected and cleared by centrifu-
gation at 5,0006 g for 10 min. The cells were placed in fresh
phenol red-free DMEM without serum and hGLuc PCA signal
was detected as described above. After measuring the PCA signal,
cells were lysed for bGal assay as described above. 25 ml of lysates
were collected to measure total cellular APP by SEAP assay. Then,
bGal assay was carried out as in a single-readout PCA.
Supernatant was split in 2 samples and analyzed separately:
25 ml of media was used to measure shed sAPP by SEAP assay and
75 ml was used to measure exosomal APP-BACE1 by PCA. PCA
and SEAP assay signals were normalized to bGal signals well by
well.
Western blots
For Western blots, cells were transfected on 6-well polystyrene
plates (Corning). 24 h after transfection, the cells were washed
twice with ice-cold PBS followed by scraping and extraction on ice
for 30 min in a buffer containing 10 mM Tris-HCl, pH 6.8,
1 mM EDTA, 150 mM NaCl, 0.25% Nonidet P-40, 1% Triton
X-100, 1 mM NaF and protease inhibitor mixture tablets (Roche
Applied Science). Cell debris was removed by centrifugation at
16,0006g. The protein concentrations were determined using the
BCA protein assay kit (Pierce/Thermo) and equal amounts of total
protein (25–40 mg) per lane were resolved in a 4–12% gradient
Live-Cell Monitoring of Cellular Fates of APP
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Bis-Tris gels (Novex, Invitrogen) under reducing conditions. After
transfer to PVDF membranes (Amersham Biosciences/GE
Healthcare), the filters were probed with the following antibodies:
A8717 (Sigma; APP C-terminus), dNGluc (Proteintech Group Inc)
and GAPDH (Millipore). After incubation with horseradish-
conjugated secondary antibodies, the signal was developed using
ECL Western blotting detection reagent (Pierce/Thermo).
Isolation of exosomal vesicles
N2A cells were plated on 10-cm plates with full DMEM. Cells
were transfected at about 50% confluency. Cells were washed
once with pre-warmed PBS and placed in serum-free, phenol red-
free DMEM. 24 h later, the conditioned media was collected for
isolation of exosomes, and the cell extracts were prepared for
Western blot analysis. Conditioned media (pooled from 6 10-cm
plates) was centrifuged successively at 2006 g for 10 min to
remove floating cells, at 2,0006g for 10 min to remove dead cells,
at 10,0006 g for 30 min at 4uC to remove the cell debris. After
each step, the supernatant was recollected without disturbing the
pellets. The cell- and debris-free supernatant was centrifuged using
a Beckman Optima L-100K centrifuge and an SW41 Ti rotor at
100,0006 g for 70 min at 4uC to collect the exosomes. The
supernatant was gently removed and the exosomal pellet
resuspended in 1 ml of PBS. The collected PBS was centrifuged
again at 100,0006 g for 70 min at 4uC. After careful removal of
the PBS supernatant, the exosomal pellet was resuspended in 40 ml
of 1.5 X Laemmli buffer (75 mM Tris-HCl, pH 6.8, 3% SDS,
15% glycerol, 3.75 mM EDTA) with b-mercaptoethanol, and
analyzed by Western blotting.
Ab ELISA
For Ab determination, N2A cells were transfected with APP-
GLuc2 plasmid on 6-well plates (Corning), and 24-h conditioned
media (serum-free) collected 48 h post-transfection. The condi-
tioned media was cleared from debris and secreted Ab40 and Ab42
were quantitated by standard sandwich ELISA (pmol/L; IBL
International GmbH, Germany). Protein concentrations of the cell
lysates were determined using the BCA protein assay kit (Pierce).
The Ab values were normalized to total protein levels (mg). Each
experiment was carried out in triplicate.
Statistical analyses
Statistical analyses were performed using analysis of variance
(ANOVA; three or more groups, followed by Bonferroni’s post-
tests) or Student’s t test (two groups) in GraphPad Prism software.
Significance was placed at p,0.05.
Results
Protein-fragment complementation assay-based
detection of APP-BACE1 interaction in live cells
Because of its pathophysiological significance, we focused on
APP-BACE1 protein-protein interaction as the first readout of the
new assay system. Split luciferase PCA technology offers a suitable
experimental strategy for developing a live-cell assay for studying
APP-BACE1 interaction dynamics. We chose a PCA based on a
small Gaussia princeps luciferase (GLuc) reporter, as it provides a
highly sensitive and reversible detection method for protein-
protein interactions [36]. Humanized GLuc protein without the
16 N-terminal amino acids was split between the Gly93 and Glu94
residues, resulting in a 93 amino-acid (10.1 kDa) GLuc1 fragment
and a 76 amino acid (8.2 kDa) GLuc2 fragment. Since APP and
BACE1 are both type 1 transmembrane proteins with relatively
short cytosolic domains, we placed GLuc1 and GLuc2 tags in the
C-termini of APP and BACE1 in both orientations (Fig. 1A). In
order to maximize the topological flexibility of the GLuc
fragments, (GGGGS)2SG linker region was placed between the
C-terminus of the protein of interest and the GLuc fragments.
GLuc-tagged proteins were expressed normally in N2A cells as
shown by the Western blots (Fig. 1B). The GLuc-tags did not
interfere with proteolytic processing pattern of APP, as APP-
GLuc1 and APP-GLuc2 fusion proteins produced a- and b-C-
terminal fragments similarly to non-tagged APP (Fig. 1B).
When single GLuc-tagged APP and BACE1 constructs were
expressed alone in N2A (with control plasmids expressing free
GLuc1/2 reporter fragments), only very low background lumi-
nescence signal was detected when the cells were exposed to native
coelenterazine, the substrate of Gaussia luciferase (Fig. 1C). When
APP-GLuc1 was co-transfected with BACE1-GLuc2 plasmid, a
robust luminescence signal was detected (Fig. 1C). Similar signal
Figure 1. Protein-fragment complementation assay-based
detection of APP and BACE1 interaction in live cells. (A)
Graphical presentation of PCA reporter constructs of APP and BACE1.
hGLuc, humanized Gaussia luciferase fragment; SP, signal peptide; TM,
transmembrane domain. (B) Normal expression and proteolytic
processing of APP-GLuc2 and BACE1-GLuc1 fusion proteins in N2A
neuroblastoma cells. Cells were transiently transfected with indicated
combinations of expression constructs and analyzed for APP fragments
and BACE1 protein in cell lysates. Western blots were probed with APP
C-terminal antibody (A8717), dNGluc antibody (detects the GLuc1
fragment) and GAPDH as a loading control. (C) Validation of GLuc-based
PCA for detection of APP-BACE1 interaction in N2A cells. Cells were
transiently transfected with indicated combinations of expression
constructs. Luminescence signal was measured 48 h post-transfection
in live cells. Normalization of cell numbers and transfection efficiency
was done with an internal vector control (using a plasmid expressing b-
galactosidase). Control plasmids were empty GLuc1/2 plasmids
expressing the indicated GLuc fragment alone. The values are
normalized bioluminescence signals recorded from expressed pairs of
reporter constructs. Error bars represent the SEM, and statistical
significance was assessed using ANOVA. *** p,0.001.
doi:10.1371/journal.pone.0098619.g001
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was detected from cells co-expressing the APP-GLuc2 and
BACE1-GLuc1. To control for specificity of APP-BACE1 PCA,
we tested APP-GLuc2 and BACE-GLuc2 interaction with GLuc1-
tagged extracellular signal-regulated kinase 2 (ERK2), a mitogen-
activated protein kinase for which direct interaction with APP or
BACE1 has not been reported. As shown in Fig. 1C, there was
very low PCA signal generated by APP-ERK2 or BACE1-ERK2
suggesting that there was no direct interaction between these
proteins.
Next, we tested the dynamics of the APP-BACE1 interaction
assay using genetic means, based on previously established
regulators of APP metabolism. Previous studies have shown that
GGA3 is an important regulator of BACE1 trafficking from
endosomes for lysosomal degradation [38]. Depletion of GGA3
stabilizes BACE1 protein increasing its levels in the endocytic
compartment and therefore results in increased Ab generation.
Similarly, knockdown of VPS35, a retromer receptor involved in
endosome-Golgi trafficking of APP, was previously reported to
promote Ab generation [39]. Thus, we decided to use GGA3 and
VPS35 RNAi as the validation tool in BACE1-APP PCA assay
development. The knockdown efficiencies of GGA3 and VPS35
shRNA were determined by Western blotting. As compared to
control cells, the expression of the corresponding shRNA’s in N2A
cells reduced GGA3 protein level by 262% and VPS35 by 253%
(data not shown). When the GGA3 and VPS35 shRNA plasmids
were co-transfected with the PCA plasmids, the BACE1-APP PCA
signal was increased by 216% in GGA3 shRNA cells (Fig. 2A).
This indicates that GGA3 knockdown increases interaction
between BACE1 and APP. To confirm that the increased
interaction correlates with an increase in Ab production, we
analyzed conditioned media from cells expressing the BACE1-
APP PCA constructs and shRNA plasmids. Ab40 and Ab42 levels
in the conditioned media were increased by 301% and 262% in
GGA3 shRNA cells, respectively (Fig. 2B), confirming that the
increased interaction measured by the PCA resulted in increased
Ab generation. VPS35 shRNA cells did not show significant
increases in Ab secretion although the BACE1-APP PCA signal
was increased by 161% in VPS35 shRNA cells. These data show
that GLuc PCA can detect changes in APP-BACE1 protein
interaction in live cells.
Simultaneous live-cell detection of BACE1-APP
interaction and shedding of APP
Since APP ectodomain release by proteolytic cleavage is the
expected outcome of the BACE1-APP interaction, we sought for
ways to combine detection of proteolytic processing of APP with
the live-cell PCA assay. Alkaline phosphatase (AP) fused to the N-
terminus of APP (after signal peptide) has been previously used to
detect secreted APP (sAPP) fragments from the conditioned media
[37]. For simultaneous detection of BACE1 interaction and
proteolytic cleavage of APP, we generated a double-fusion
construct of APP, which contains an N-terminal AP fusion and
a C-terminal GLuc-fusion (Fig. 3A). This allows using a sensitive
luminescence-based assay (SEAP= secreted alkaline phosphatase
assay) for detection of sAPP fragments from the conditioned
media. The AP-APP-GLuc2 was expressed and processed
normally in N2A cells, as compared to the APP-GLuc2 construct
that does not have the AP fusion (Fig. 3B). Next, accumulation of
shed sAPP from cleared, conditioned media was analyzed. SEAP
assay detected sAPP from media as early as 2 h after media
change, and showed a linear curve of sAPP production at least up
to 18 hours (Fig. 3C; R2= 0.9782).
Optimally the shedding assay would detect only sAPP-b
fragments derived from BACE1-mediated cleavage of APP. In
order to make the assay specific for analysis of sAPP-b, we tested
blocking of a-secretase-mediated processing of APP via genetic
means. We introduced the F615P mutation (according to APP695
numbering) close to the a-secretase cleavage site in the AP/APP-
GLuc2 construct. This mutation was previously reported to reduce
sAPP secretion by .60% [40]. We observed only a minor shift
towards b-cleavage, not a complete blockage of a-processing (data
not shown). This observation was supported by a recent study
showing that F615P mutation can only partially inhibit a-secretase
cleavage of APP [41]. Therefore, we decided that the APP
cleavage assay readout shall be the total sAPP (sAPP-a+sAPP-b) in
media as determined by the SEAP assay.
Next, we used pharmacological tools to functionally validate the
two-parameter assay. Brefeldin A (BFA) inhibits the transport of
secretory and membrane proteins from the ER to the Golgi.
Retention of APP in the early secretory pathway has been reported
to reduce the proteolytic processing of APP and shedding of sAPP
fragments to media [17,42]. In line with the previous reports,
treatment of cells with BFA strongly reduced sAPP shedding
(Fig. 3D; SEAP signal in the media). Interestingly, BFA increased
the interaction between APP and BACE1, likely due to their
Figure 2. Functional assay validation of GLuc PCA for APP-BACE1 interaction. For genetic assay validation of BACE1-APP PCA, plasmids
expressing GGA3 and VPS35 shRNA were cotransfected to N2A cells with plasmids encoding BACE1-GLuc1 and APP-GLuc2 reporters. (A) PCA signal
was measured at 48 h post-transfection. (B) Ab40 and Ab42 in conditioned media were determined by sandwich ELISA. The number of replicate wells
for PCA was four (96-well plate) and for Ab ELISA two (6-well plate). Error bars represent the SEM, and statistical significance was assessed using
ANOVA. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0098619.g002
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accumulation in the ER (Fig. 3D, PCA data on the left panel).
Inhibition of b-cleavage of APP by BACE inhibitor IV, a BACE1
active-site binding compound, reduced the amount of total
secreted sAPP in media by 35% while increasing the APP-BACE1
interaction by 22% (Fig. 3E). This suggests that inhibitor-bound
BACE1 molecules can still interact with APP although the actual
enzymatic cleavage of APP is inhibited.
Endocytosis is required for internalization of APP and BACE1
from the cell surface [43–45] to the endocytic compartment where
BACE1 activity is increased by acidification of the vesicle lumen
[35]. Inhibition of endocytosis reduces APP internalization and
reduces Ab production in cell lines [19,46]. Dynole 34-2, a cell-
permeable small-molecule inhibitor of dynamin-dependent endo-
cytosis [47], significantly inhibited sAPP secretion (237%) but
increased APP-BACE1 interaction by 95% (Fig. 3F). This pattern
is similar to BACE1 inhibition and suggests that conditions
interfering with internalization of APP and BACE1 or inhibition of
BACE1 activity increase the interaction between the two proteins
although BACE1-mediated by proteolytic processing of APP is
reduced. Moreover, these data show that the two-readout
multiplex assay of AP/APP-BACE1 interaction and APP shedding
responds to known modulators of APP-BACE1 trafficking and
processing in a predictable manner.
Exosomal secretion of APP and BACE1 PCA reporter
proteins
One potential complicating factor for interpretation of the
SEAP assay signal from conditioned media could be the presence
of uncleaved APP holoprotein in the media. Exosomal release of
APP holoprotein, its metabolites and BACE1 by neuronal cells in
vitro and in vivo has been reported [48]. Also, overexpression may
result in enhanced exosomal release of reporter proteins.
Therefore, it is possible the SEAP assay signal represents the
combined pool of shedded sAPP and exosomal APP holoprotein,
although the exosomal fraction of APP holoprotein is likely to be
small as compared to the sAPP fraction. In order to monitor this,
we analyzed cell-free conditioned media for the presence of AP/
APP-BACE1 complex, as determined by the AP/APP-BACE1
PCA. As shown in Fig. 4A, there is a robust accumulation of AP/
APP-BACE1 PCA signal in cleared, conditioned media that
showed good linearity at least up to 18 hours (R2= 0.9667). N2A
cells constitutively release exosomes enriched in Alix, a multive-
Figure 3. Multiplex assay for simultaneous live-cell detection
of APP-BACE1 interaction and proteolytic cleavage of APP. (A)
Graphical presentation of the multiplex PCA reporter constructs.
Alkaline phosphatase (AP) with a signal peptide was placed in the N-
terminus of APP-GLuc2. AP reporter is depicted in beige and GLuc
reporter in red color. The same colors are used in column graphs in
Fig. 3B–F for corresponding reporter data. (B) Normal proteolytic
processing of the AP/APP-hGLuc fusion protein in N2A cells. Cells were
transiently transfected with indicated combinations of various APP
constructs: APP-GLuc2 and AP/APP-GLuc2 and BACE1-GLuc1. Western
blots were probed with APP C-terminal antibody (A8717), dNGluc
(BACE1) and GAPDH as a loading control. (C) Sensitivity and linearity of
secreted alkaline phosphatase-sAPP (SEAP) assay from conditioned
media. N2A cells were transiently transfected with BACE1-GLuc1 and
AP/APP-GLuc2. Cells were incubated in serum-free media for up to
30 hours (inset graph shows data up to 60 h). AP activity in cell-free
conditioned media was detected using a chemiluminescent SEAP assay.
Normalization of cell numbers and transfection efficiency was done
with an internal vector control (using a plasmid expressing b-
galactosidase). The values are normalized chemiluminescence signals
recorded from expressed pair of constructs. The number of replicate
wells was four. Linearity of data was evaluated by regression analysis;
correlation coefficient (R2) was 0.98806. Error bars represent the SEM.
(D) Effects of brefeldin A (BFA) in the multiplex assay (PCA+AP data).
N2A cells were transiently transfected with BACE1-GLuc1 and AP-APP-
GLuc2, and treated with indicated concentration of BFA for 24 h before
measurement of PCA and SEAP signals (48 h after transfection). The
average values are displayed as percentage of change as compared to
vehicle-treated control cells. (E) Effects of BACE inhibitor IV in the
multiplex assay (PCA+AP data). N2A cells were transfected as in D, and
treated with indicated concentration of BACE inhibitor IV for 6 h before
measurement PCA and SEAP signals (48 h after transfection). The
average values are displayed as percentage of change as compared to
vehicle-treated control cells. (F) Effects of dynole 34-2 in the multiplex
assay (PCA+AP data). N2A cells were transfected as in D, and treated
with indicated concentration of dynole 34-2 for 6 h before measure-
ment PCA and SEAP signals (48 h after transfection). The average values
are displayed as percentage of change as compared to vehicle-treated
control cells. Error bars represent the SEM, and statistical significance
was assessed using Student’s t test (four replicate wells/experiment,
four independent experiments). * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0098619.g003
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sicular body protein commonly used as an exosomal marker [49].
To confirm that the AP/APP-BACE1 PCA reporters are found in
exosomes, we isolated exomes from the conditioned media using
the widely used method described by The´ry et al [50]. As shown in
Fig. 4B, both AP/APP-GLuc2 and BACE1-GLuc1 PCA reporters
were found in Alix-positive exosomes purified from the media
using the serial ultracentrifugation method.
To verify that the presence of AP/APP-BACE1 PCA signal in
the conditioned media is associated with exosomal secretion, we
tested if inhibition of exosome biogenesis would decrease the
amount of APP-BACE1 PCA signal in the conditioned media.
Sphingolipid metabolism, ceramide in particular, is an important
regulator exosome biogenesis. Ceramide is the key regulator of
cargo segregation into distinct subdomains of the endosomal
membrane before budding of exosomal vesicles into multivesicular
endosomes [51]. Inhibition of neutral sphingomyelinase (nSMase),
which converts sphingomyelin to ceramide, by GW-4869 signif-
icantly inhibited accumulation of AP/APP-BACE1 PCA signal in
the conditioned media (262%; Fig. 4C). These data suggest that 1)
both APP and BACE1 holoproteins can be released from cells in
association with exosomes, and 2) that AP/APP-BACE1 PCA in
the conditioned media can be used as a readout of the exosomal
release activity of these proteins. Thus, analysis of exosomal
secretion of APP and BACE1 adds another multiplexing
dimension for analyzing APP trafficking in live cells.
Four-parameter multiplex assay for analyzing cellular fate
of APP
Separation of conditioned media from the cell monolayer allows
parallel analysis of multiple readouts. In addition to detection of
APP-BACE1 interaction in cells and in secreted exosomes, and
total sAPP in media, we used cell-based SEAP signal as a readout
of total cellular APP levels. Although a small fraction of the cell-
derived SEAP signal likely comes from intracellular sAPP
fragments, the vast majority of the signal is derived from APP
holoprotein (mature and immature). This is also supported by
previous reports [52]. Fig. 5A summarizes the workflow and
analyses of different samples in the four-parameter multiplex
assay. The average interassay variation was determined for each
assay readout by the Coefficient of Variation (%CV), the standard
deviation across multiple independent assays expressed as a
percentage of the mean (in AP-APP-Gluc2/BACE-GLuc1 trans-
fected cells with no experimental treatments). For total cellular
APP (SEAP) %CV was 12.562.5%, for shed APP in media
(SEAP) 17.164.8%, for APP-BACE1 interaction in cells (PCA)
9.963.2% and for exosomal APP-BACE1 complexes in media
(PCA) 12.260.9% (n= 4 replicate experiments). This variation is
acceptable for a cell-based assay using transient transfection,
according to the widely used criteria in high-throughput assay
development (well-to-well %CV should be less than 20%) [53].
We used pharmacological tools previously shown to affect
cellular trafficking of APP differentially to test the responsiveness
of the four-parameter multiplex APP assay. In addition to
compounds used in Figs. 3–4, we added three more compounds
for further functional validation. DAPT, a c-secretase inhibitor
[54], acts downstream of BACE1 in the sequential APP proteolytic
processing cascade, and is thus not expected to have significant
effects in the four-parameter multiplex assay, that mostly focuses
on events that operate upstream of c-secretase. Bafilomycin A1, a
vacuolar H+-ATPase inhibitor, reduces amyloidogenic processing
of APP [55]. Interestingly, bafilomycin A1 also increases cellular
release of exosomes [56], likely to compensate for the reduced
autophagic/lysosomal degradative capacity in the cells.
The compiled data in Fig. 5B show that the four-parameter
multiplex assay responds to all tested experimental conditions in a
predictable way, and that the cellular fates of APP in different
conditions are quite distinctive. For clarity, the sites of action of the
validation compounds are summarized in Fig. 5C. Brefeldin A
strongly reduces sAPP secretion due to its effects on early secretory
pathway trafficking. BFA results in accumulation of APP and
Figure 4. Exosomal secretion of AP/APP and BACE1 PCA reporter proteins. (A) Detection of AP/APP-BACE1 PCA signal in cleared, cell- and
debris-free conditioned media. N2A cells were transiently transfected with BACE1-GLuc1 and AP/APP-GLuc2. Cells were incubated in serum-free
media for up to 18 hours. PCA signals in cell-free conditioned media were detected at indicated time points. Normalization of cell numbers and
transfection efficiency was done with an internal vector control. The values are normalized bioluminescence signals recorded from expressed pair of
constructs. The number of replicate wells was four. The linearity was evaluated by regression analysis, correlation coefficient (R2) is 0.9971. Error bars
represent the SEM. (B) N2A cells were transfected with AP/APP-GLuc2 and BACE1-GLuc1 reporter plasmids. Exosomes were isolated from 30-h
conditioned media (inset graph shows data up to 60 h) by ultracentrifugation and the presence of AP/APP-GLuc2 and BACE1-GLuc1 reporters in
exosomes was analyzed by Western blotting using antibodies for APP (C-terminal antibody A8717), dNGluc (BACE1) and Alix as an exosomal marker.
Total cell extracts were analyzed in parallel with the isolated exosome fraction. (C) Pharmacological modulation of ceramide levels alters exosomal
secretion of AP/APP-BACE1 PCA reporters. N2A cells were transiently transfected with BACE1-GLuc1 and AP/APP-GLuc2, and treated with 10 mM of
GW-4869, the neutral sphingomyelinase (nSMase) inhibitor, for 24 h. PCA signal in cell-free conditioned media was measured at 48 h after
transfection. Normalization of cell numbers and transfection efficiency was done with an internal vector control. The average values are displayed as
percentage of change as compared to vehicle-treated control cells. Error bars represent the SEM, and statistical significance was assessed using
Student’s t test (four replicate wells/experiment, four independent experiments). *** p,0.001.
doi:10.1371/journal.pone.0098619.g004
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BACE1 to the ER, which in this assay is reflected as an increase in
APP-BACE1 interaction. BACE inhibitor IV and dynole 34-2
modulate the BACE1-cleavage of APP via different mechanisms
and have somewhat similar effects on the four assay readouts.
Inhibition of c-secretase by DAPT shows little effects on the four
readouts. Bafilomycin A1 has the strongest overall effects on APP
and BACE1 underscoring its strong impact on endocytic function
and lysosomal/autophagic clearance of proteins. Modulation of
sphingomyelin-ceramide conversion by GW-4869 not only affects
exosomal secretion of APP-BACE1 complex but also strongly
reduces sAPP shedding. Cellular levels of ceramide modulate the
function of lipid rafts [57], and may also directly affect b-cleavage
of APP via altered stability of BACE1 protein [58]. Altogether,
these data show that modulation of different sites of the cellular
trafficking machinery of APP and BACE1 produces distinctive
patterns that can be effectively recognized by the new live-cell
assay system.
Discussion
Here we describe a high-throughput capable live-cell assay
system that can rapidly give mechanistic insight into how cellular
trafficking of APP is altered by a given perturbation. The assay was
developed around live-cell detection of APP-BACE1 protein-
protein interaction. The final outcome of the APP-BACE1
interaction – whether APP is cleaved by BACE1 or not – is
determined by a wide range of factors. Various subcellular
trafficking events determine when, where and for how long APP
and BACE1 are allowed to interact within the cell [22]. Moreover,
the local microenvironment where the interaction takes place
determines whether BACE1 is able to cleave APP, as for example
lower intravesicular pH is required for optimal BACE1 enzyme
activity [35].
The APP interactome is very large, with many cytosolic domain
interactions that regulate its subcellular trafficking and proteolytic
processing [28]. New insights into the cellular regulation of the
interactions and trafficking of APP can improve our understanding
of normal physiological functions of APP and the cellular rationale
behind its complex proteolytic processing machinery. Better
understanding of the cellular fates of APP can provide new
information on how genetic and environmental factors contribute
to AD pathogenesis, and offer novel ways for restoring disease
pathology to the normal cellular state, e.g. via modulation of key
protein-protein interactions of APP. The outcome of our four-
parameter multiplex live-cell assay is a distinct fingerprint of the
cellular fate of APP, with immediate mechanistic insight, upon
changing pharmacological, genetic or metabolic conditions. This
feature combined with the high-throughput nature of the assay sets
this new technique clearly apart from the existing methods to study
cellular regulation of APP.
Expectedly, majority of the proof-of-concept data produced
using the novel live-cell APP multiplex assay is in line with
previously published reports in the field. Inhibition of the vacuolar
H+-ATPase by bafilomycin A1 produced the most robust increase
in APP-BACE1 interaction, likely due to reduced efficiency of
BACE1-mediated APP cleavage in endosomes with elevated
intraluminal pH [55,59]. c-secretase inhibition by DAPT had
minor effects on the overall pattern of APP interactions and a/b-
secretase processing, although a minor and consistent increase in
total cellular APP was observed. Similar observations have been
reported previously [60].
Genetic manipulation of proteins involved in vesicular traffick-
ing of APP and BACE1, such as GGA3 and VPS35, increased
APP-BACE1 interaction, which is in line with previous reports
Figure 5. Four-parameter multiplex assay for detection of
cellular fates of APP. (A) Workflow and separation of samples for
different analyses in the four-endpoint multiplex assay. Colors refer to
the parameter/analyte used in the multivariate analysis graph in Fig. 5B.
PCA and SEAP signals were read from both conditioned media and cell
monolayer (in fresh media) and represent the presence of BACE1-APP
complex and APP/sAPP species in different compartments. (B)
Multivariate analysis of PCA and SEAP data from cells treated with
brefeldin A, dynole 34-2, BACE1 inhibitor IV, DAPT, bafilomycin A1 and
GW-4869. N2A cells were transiently transfected with BACE1-GLuc1 and
AP/APP-GLuc2, and treated with indicated chemicals for 6 h (1 mM
BACE inhibitor IV, 0.5 mM DAPT, 10 mM Dynole 34-2) or 24 h (100 nM
bafilomycin, 5 mg/ml brefeldin A, 10 mM GW-4869) before measurement
of PCA and SEAP signals (48 h after transfection). The average values
are displayed as percentage of change as compared to vehicle-treated
control cells. Error bars represent the SEM, and statistical significance
was assessed using ANOVA (four replicate wells/experiment, four
independent experiments). * p,0.05, ** p,0.01, *** p,0.001. (C)
Schematic diagram showing the sites of action of the chemicals used in
multiplex PCA in Fig. 5B. Brefeldin A inhibits the transport of secretory
and membrane proteins from the ER to the Golgi. Bafilomycin A1, an
inhibitor of vacuolar proton ATPases, prevents intravesicular acidifica-
tion. Dynole 34-2 is an inhibitor of dynamin-dependent endocytosis.
GW-4869, neutral sphingomyelinase inhibitor, reduces the exosomal
secretion. BACE inhibitor IV and DAPT inhibit b- and c-secretase
cleavage of APP, respectively.
doi:10.1371/journal.pone.0098619.g005
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[38,61]. However, only GGA3 silencing had a strong effect on Ab
levels. There are controversial reports on how VPS35 silencing
affects Ab secretion; both increase [39] and decrease [62] of Ab40
generation has been reported. These discrepancies may be
explained by differences between cell lines or other experimental
conditions, such as transfection and gene silencing efficiency, used
in various studies. Moreover, in addition to its role in retrograde
endosome-Golgi trafficking, VPS35 may also be involved in
regulation of exosomal secretion [62]. In support of previous
findings [48,63], we also report the presence of APP, C-terminal
fragments and BACE1 in secreted exosomes. Our multiplex assay
system offers a novel, highly sensitive tool to study the dynamics of
exosomal secretion of APP and BACE1. In general, parallel
assessment of multiple pathways may provide new insight into
complex subcellular trafficking itineraries of APP. For example,
sphingolipid metabolism modulates trafficking and processing of
APP and BACE1 on multiple levels. Using the multiplex APP
PCA, the strong effects of nSMase inhibition by GW-4869 on both
shedding and exosomal secretion of APP were revealed, suggesting
the involvement of ceramide in both processes.
There are two obvious caveats with the multiplex APP assay.
First, analysis of sAPP is not specific to the sAPP-b form but
detects both the sAPP-a and sAPP-b forms. Using a mutation near
the a-cleavage site to block a-secretase cleavage is an attractive
strategy but this would require near-full inhibition, which cannot
be achieved with the F615P mutation [40,41]. Secondly, the assay
requires overexpression of APP and BACE1. Although this may
alter the natural trafficking and processing machinery or the
cellular localization of the reporters to some degree, it should be
noted that most cell lines and transgenic animal models used in
AD research similarly rely on overexpression of APP. Currently,
the assay relies on transient transfection but for more extensive
screening studies better control of the overexpression level of the
reporter proteins would require generation of a stable reporter cell
line.
Sporadic forms of neurodegenerative diseases are complex and
their etiologies cannot be narrowed down to a small number of
effector genes. Particularly, in the case of late-onset Alzheimer’s
disease (LOAD), which comprises more than 95% of the AD
patient population, the functional connections of the risk genes to
the known pathophysiological pathways of the disease remains
poorly understood. In the post-GWAS-era, a major bottleneck is
functional characterization of novel disease-associated genes. Cell-
based assays that facilitate rapid screening of functional connec-
tions of novel disease-associated genes to known pathophysiolog-
ical pathways of the disease could significantly accelerate this
process. Current methods used to study APP-related aspects of AD
pathogenesis mostly rely on analyzing protein complexes in cell or
tissue extracts. Live-cell methods are more suitable for studying the
dynamics of cellular trafficking of disease-associated proteins and
their protein interactions, and may reveal new subtle nuances in
cellular regulation of proteins of interest, while providing high-
throughput abilities. Our multiplex live-cell assay provides a
sensitive and dynamic reporter system that responds predictably to
stimuli known to modulate amyloidogenic processing of APP in
cells. This offers a novel and rapid way of addressing mechanistic
aspects of e.g. altered amyloidogenic processing of APP in cells.
Therefore, our novel assay platform offers significant advantages
for various screening approaches, from drug discovery to
functional characterization of late-onset AD risk genes.
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